| Primary |
| Product Used For Unknown Indication |
29.8% |
| Prophylaxis |
14.0% |
| B-cell Lymphoma |
7.0% |
| Urinary Tract Infection |
7.0% |
| Chronic Lymphocytic Leukaemia |
5.3% |
| Cytomegalovirus Infection |
5.3% |
| Antibiotic Prophylaxis |
3.5% |
| Graft Haemorrhage |
3.5% |
| Hypothyroidism |
3.5% |
| Pneumonia |
3.5% |
| Anxiety |
1.8% |
| Aspergillus Infection |
1.8% |
| Cholestasis |
1.8% |
| Depression |
1.8% |
| Diarrhoea |
1.8% |
| Hypertension |
1.8% |
| Hyperuricaemia |
1.8% |
| Immunosuppression |
1.8% |
| Insomnia |
1.8% |
| Oedema Peripheral |
1.8% |
|
| Drug Reaction With Eosinophilia And Systemic Symptoms |
14.3% |
| International Normalised Ratio Increased |
14.3% |
| Leukopenia |
14.3% |
| Rash Pruritic |
14.3% |
| Renal Failure Acute |
14.3% |
| Thrombotic Microangiopathy |
14.3% |
| Toxic Skin Eruption |
14.3% |
|
| Secondary |
| Product Used For Unknown Indication |
47.6% |
| Prophylaxis |
9.9% |
| Drug Therapy |
5.8% |
| Cytomegalovirus Infection |
4.4% |
| Cord Blood Transplant Therapy |
3.9% |
| Osteitis |
3.1% |
| Chronic Lymphocytic Leukaemia |
2.7% |
| Plasma Cell Myeloma |
2.3% |
| Insomnia |
2.1% |
| Hiv Infection |
1.9% |
| Chemotherapy |
1.7% |
| Eschar |
1.7% |
| Hypertension |
1.7% |
| Pathogen Resistance |
1.7% |
| B-cell Lymphoma |
1.5% |
| Depression |
1.5% |
| Drug Use For Unknown Indication |
1.5% |
| Hiv Test Positive |
1.5% |
| Partial Seizures |
1.5% |
| Prevention |
1.5% |
|
| Thrombotic Microangiopathy |
11.3% |
| Hypertriglyceridaemia |
9.7% |
| Pancytopenia |
8.1% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
6.5% |
| Neutropenia |
6.5% |
| Renal Failure Acute |
6.5% |
| Cytolytic Hepatitis |
4.8% |
| Neuropathy Peripheral |
4.8% |
| Staphylococcal Bacteraemia |
4.8% |
| Toxic Epidermal Necrolysis |
4.8% |
| Agranulocytosis |
3.2% |
| Exposure During Pregnancy |
3.2% |
| International Normalised Ratio Increased |
3.2% |
| Mixed Liver Injury |
3.2% |
| Pneumocystis Jirovecii Pneumonia |
3.2% |
| Rash |
3.2% |
| Rash Pustular |
3.2% |
| Skin Exfoliation |
3.2% |
| Thrombocytopenia |
3.2% |
| Tremor |
3.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
41.3% |
| Prophylaxis |
5.9% |
| Plasma Cell Myeloma |
5.8% |
| Chronic Lymphocytic Leukaemia |
5.6% |
| Prophylaxis Against Renal Transplant Rejection |
5.6% |
| Drug Use For Unknown Indication |
5.5% |
| Infection Prophylaxis |
3.7% |
| Renal Transplant |
3.5% |
| Hiv Infection |
3.4% |
| Hypertension |
2.7% |
| Mantle Cell Lymphoma |
2.1% |
| Multiple Myeloma |
2.1% |
| Premedication |
2.1% |
| B-cell Lymphoma |
1.8% |
| Diabetes Mellitus |
1.8% |
| Non-hodgkin's Lymphoma |
1.8% |
| Lung Infection |
1.6% |
| Thrombosis Prophylaxis |
1.4% |
| Aspergillosis |
1.3% |
| Epilepsy |
1.1% |
|
| Pyrexia |
10.3% |
| Septic Shock |
8.6% |
| Thrombocytopenia |
8.6% |
| Lung Disorder |
5.2% |
| Myelodysplastic Syndrome |
5.2% |
| Pulmonary Embolism |
5.2% |
| Rash Maculo-papular |
5.2% |
| Renal Failure Acute |
5.2% |
| Thrombotic Microangiopathy |
5.2% |
| Tremor |
5.2% |
| Tubulointerstitial Nephritis |
5.2% |
| Agranulocytosis |
3.4% |
| Bronchopneumopathy |
3.4% |
| Cerebral Infarction |
3.4% |
| Febrile Neutropenia |
3.4% |
| Hepatocellular Injury |
3.4% |
| Mixed Liver Injury |
3.4% |
| Muscle Haemorrhage |
3.4% |
| Pancytopenia |
3.4% |
| Pneumonia Pseudomonas Aeruginosa |
3.4% |
|
| Interacting |
| B-cell Lymphoma Stage Iv |
66.7% |
| Urinary Tract Infection |
20.0% |
| Depression |
6.7% |
| Venous Thrombosis |
6.7% |
|
| Renal Failure Acute |
50.0% |
| Rectal Haemorrhage |
25.0% |
| Renal Failure |
25.0% |
|
